Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1152/ajpcell.00187.2020

http://scihub22266oqcxt.onion/10.1152/ajpcell.00187.2020
suck pdf from google scholar
32515982!7381713!32515982
unlimited free pdf from europmc32515982    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32515982      Am+J+Physiol+Cell+Physiol 2020 ; 319 (2): C244-C249
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • H(2)S as a potential defense against COVID-19? #MMPMID32515982
  • Yang G
  • Am J Physiol Cell Physiol 2020[Aug]; 319 (2): C244-C249 PMID32515982show ga
  • The outbreak of COVID-19 pneumonia caused by a new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is posing a global health emergency and has led to more than 380,000 deaths worldwide. The cell entry of SARS-CoV-2 depends on two host proteins angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). There is currently no vaccine available and also no effective drug for the treatment of COVID-19. Hydrogen sulfide (H(2)S) as a novel gasotransmitter has been shown to protect against lung damage via its anti-inflammation, antioxidative stress, antiviral, prosurvival, and antiaging effects. In light of the research advances on H(2)S signaling in biology and medicine, this review proposed H(2)S as a potential defense against COVID-19. It is suggested that H(2)S may block SARS-CoV-2 entry into host cells by interfering with ACE2 and TMPRSS2, inhibit SARS-CoV-2 replication by attenuating virus assembly/release, and protect SARS-CoV-2-induced lung damage by suppressing immune response and inflammation development. Preclinical studies and clinical trials with slow-releasing H(2)S donor(s) or the activators of endogenous H(2)S-generating enzymes should be considered as a preventative treatment or therapy for COVID-19.
  • |Angiotensin-Converting Enzyme 2[MESH]
  • |Animals[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Betacoronavirus/*drug effects/pathogenicity[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |Coronavirus Infections/*drug therapy/metabolism/virology[MESH]
  • |Host-Pathogen Interactions[MESH]
  • |Humans[MESH]
  • |Hydrogen Sulfide/metabolism/*therapeutic use[MESH]
  • |Lung/drug effects/metabolism/virology[MESH]
  • |Pandemics[MESH]
  • |Peptidyl-Dipeptidase A/metabolism[MESH]
  • |Pneumonia, Viral/*drug therapy/metabolism/virology[MESH]
  • |SARS-CoV-2[MESH]
  • |Serine Endopeptidases/metabolism[MESH]
  • |Signal Transduction[MESH]
  • |Virus Internalization/*drug effects[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box